



ASX ANNOUNCEMENT

\$748K R&D TAX CREDIT RECEIVED

SYDNEY, Tuesday, 2 October 2012: Cellmid Limited (ASX: CDY) today received \$748,193 cash refund under the Federal Government's R&D Tax Incentives Scheme.

The tax refund relates to the costs of research and development conducted by the Company during the 2012 financial year and was calculated as 45% of eligible expenditure.

The funds will be used to advance Cellmid's midkine product development programs.

End

Contact:

David King, Chairman

T +612 9299 0311

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development programme is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

Advangen International Pty Ltd

Advangen International Pty Ltd is a controlled entity of Cellmid Limited. Advangen develops and sells scientifically validated products to prevent and treat various forms of hair loss. The Company's products have well understood mechanism of action and have been extensively tested for safety and efficacy with published validation data. Advangen has two market ready product ranges, one for pharmacies (évolis®) and one for professional hair salons (Jo-Ju® and Lexilis®). In addition, the Company is developing midkine in a high performance formulation for the treatment of age related hair loss.